First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program Study explores Alpha DaRT® combined with chemotherapy in patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma Up to 87% of newly diagnosed pancreatic cancer patients are considered inoperable at diagnosis and face a dismal prognosis, with limited benefit... Read More